Adverse Drug Reaction Reporting and Prescribing Trends of Drugs for Attention Deficit Hyperactivity Disorder in Primary Care England, 2010–2019

Syed Shahzad Hasan, Nimrata Bal, Isabelle Baker, Chia Siang Kow, Muhammad Umair Khan

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Objective: We investigated the prescription trends and adverse drug reactions (ADRs) of ADHD drugs in primary care, England between 2010 and 2019. Methods: The Prescription Cost Analysis database presenting the primary care prescriptions data and the Interactive Drug Analysis Profiles presenting all suspected ADRs reported for each drug were screened. The data were analyzed using linear regression analysis to examine the annual average change per year. Results: The prescription items dispensed for ADHD showed an average 11.07% (95% CI 10.54–11.60, p=.001) increase per year and there was a mean 11.54% (95% CI 11.03–12.06, p=.001) increase per year in the costs. The overall reporting of serious and fatal ADR was reduced by 1.79% per year for ADHD drugs. Guanfacine showed a 40% mean increase per year. Conclusion: The increasing use of ADHD drugs within primary care in England could be a result of multiple factors such as growing ADHD prevalence.
Original languageEnglish
Number of pages9
JournalJournal of Attention Disorders
Early online date5 Mar 2021
DOIs
Publication statusE-pub ahead of print - 5 Mar 2021

Fingerprint

Dive into the research topics of 'Adverse Drug Reaction Reporting and Prescribing Trends of Drugs for Attention Deficit Hyperactivity Disorder in Primary Care England, 2010–2019'. Together they form a unique fingerprint.

Cite this